Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.

Abstract

The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

• Authors: Janessa M Smith, Edina Avdic, Pranita D Tamma, Long Zhang, Karen C Carroll, Sara E Cosgrove
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 59 Issue 8 Pg. 5049-51 (Aug 2015) ISSN: 1098-6596 [Electronic] United States
• PMID: 26033720 (Publication Type: Journal Article)
• Copyright: Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Chemical References

• Anti-Bacterial Agents
• beta-Lactamase Inhibitors
• beta-Lactams
• Ertapenem

Topics

• Adult
• Anti-Bacterial Agents (therapeutic use)
• Bacteremia (drug therapy)
• Bacteroides (classification, drug effects)
• Bacteroides Infections (drug therapy, epidemiology)
• Case-Control Studies
• Drug Resistance, Bacterial
• Drug Therapy, Combination
• Ertapenem
• Humans
• Microbial Sensitivity Tests
• Retrospective Studies
• Risk Factors
• Tertiary Care Centers
• beta-Lactamase Inhibitors (therapeutic use)
• beta-Lactams (therapeutic use)